Tag: Sapien 3
Edwards’ Sapien 3 lands US FDA approval for the treatment of asymptomatic severe AS
Edwards Lifesciences ...
ACC 2019: TAVI moves to the mainstream with new findings in low-risk patients
Evidence for the use of t...
Enrolment complete in CT imaging substudy of leaflet mobility with Sapien 3 in low-risk patients
Edwards Lifesciences ...
TCT 2017: TMVI in mitral ring is a reasonable alternative for high-risk patients
Data from the MITRAL ...
TCT 2017: TAVI “should be the preferred strategy” for patients at intermediate-risk
David Cohen (Saint Lu...
UK Patents Court makes initial decision on Edwards Sapien 3 and Boston Scientific’s patents
The Patents Court in ...
TCT 2016: Transfemoral TAVI improves quality of life in intermediate-risk patients
Data presented at the...
Sapien 3 now approved for intermediate-risk patients in Europe as well as in the USA
Following last month’...
